Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
50,000
Stocks News & Analysis
stocks
ASX major bank drives strong quarterly profit
Profit momentum remains robust yet shares overvalued.
stocks
Ask the analyst: What to expect in earnings season?
The key metrics that matter this earnings season.
stocks
ASX healthcare share remains undervalued ahead of earnings
Margin recovery remains the key driver for this ASX healthcare share.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,063.80 | 36.20 | 0.40% |
| CAC 40 | 8,406.06 | 33.78 | 0.40% |
| DAX 40 | 25,361.03 | 262.03 | 1.04% |
| Dow JONES (US) | 52,069.05 | 121.80 | 0.23% |
| FTSE 100 | 10,781.75 | 45.52 | 0.42% |
| HKSE | 25,207.18 | 243.95 | 0.98% |
| NASDAQ | 24,849.48 | 126.34 | -0.51% |
| Nikkei 225 | 64,931.19 | 320.04 | 0.50% |
| NZX 50 Index | 13,850.69 | 78.40 | 0.57% |
| S&P 500 | 7,396.24 | 15.74 | -0.21% |
| S&P/ASX 200 | 8,894.00 | 36.10 | 0.41% |
| SSE Composite Index | 3,858.25 | 44.05 | 1.15% |